[{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"||IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Defensin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"George Mason University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"||IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ George Mason University","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ George Mason University"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Kevetrin","moa":"p53 protein","graph1":"Oncology","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Defensin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Defensin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Innovation Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
